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Select: Stem Cell ReprogrammingThe remarkable progress of the stem cell field continues at a rapid pace due, in large part, to
advances in understanding how somatic cells are reprogrammed to pluripotency. This issue’s Select
highlights recent technical developments in stem cell reprogramming and discusses newly revealed
links between induced pluripotency and cancer.Principle component analysis of miRNA profiles
identifies a group of human pluripotent stem cells
that share a common p53-linked signature with
cancer cells. Image courtesy of P. Neveu.Molecular Cartography for Stem Cells
Researchers have long suspected that cancer cells and stem cells share
a core molecular signature, but this commonality remains incompletely
understood. By examining microRNA (miRNA) expression patterns in
multiple types of cancer cells and stem cells, Neveu et al. (2010) have
now developed the miRMap, a tool that facilitates quantitative examina-
tion of the molecular hallmarks associated with a cell’s identity. Their
effort resulted in a catalog of expression patterns for nearly 330 miRNAs
in over 50 different human cell lines. Despite the overwhelming molecular
heterogeneity among the samples, their analysis identifies 11 miRNAs
that comprise a signature common to all cancer cells and shared by
a subset of pluripotent stem cells. The genes targeted by these miRNAs
downregulate cell proliferation or upregulate the p53 network. Although
recent reports have called attention to the inherent oncogenic risk of
stem cells, this new study shows that only some pluripotent stem cells
look like cancer cells, and this cancer-like state cannot be predicted
by a stem cell’s tissue of origin or method of production. By examining
the changes associated with cellular reprogramming—both when stem
cells are generated from somatic cells and when induced pluripotent
stem cells (iPSCs) are differentiated—Neveu et al. reveal a precisewindow for cancer-like behavior during iPSC generation, emphasizing that a transient downregulation of p53, rather
than a complete inhibition, is required to fully reprogram somatic cells into pluripotent stem cells. Multidimensional
molecular maps, such as the miRMap, help us draw a more complete picture of the events that drive the acquisition
of specific cell fates during cellular reprogramming.
P. Neveu et al. (2010). Cell Stem Cell 7, 671–681.LincRNA-RoR becomes activated and supports the
survival of emerging iPSCs during reprogramming
of human somatic cells. Image courtesy of
S. Loewer.Reprogramming Gets a Boost from LincRNAs
Although much recent work has uncovered the gene expression
patterns indicative of pluripotent stem cells, we know far less about
the status of the noncoding parts of the genome. Loewer et al.
(2010) now begin to fill this gap with their discovery that more than
200 large intergenic noncoding RNAs (lincRNAs) are differentially ex-
pressed in pluripotent stem cells versus somatic cells. They go on to
analyze transcriptome profiles of multiple cell types, compare the levels
of stem cell-specific lincRNAs in hESCs and iPSCs, and extract new
information about the role of lincRs in cellular reprogramming. Previ-
ously, lincRNAs have been implicated in the chromatin remodeling
events that promote the cell fate changes responsible for oncogenesis.
With this study, lincRNAs are now implicated in the reprogramming
events associated with iPSC formation, with three of them acting
directly downstream of the canonical pluripotency transcription factors Oct4, Sox2, and Nanog. One of these
lincRNAs, named RoR (regulator of reprogramming), encourages the establishment and maintenance of iPSC fate
by inhibiting the p53-mediated stress response. Similar to established methods that suppress p53 activity, overex-
pression of lincRNA-RoR provides a 2-fold increase in the efficiency of iPSC generation guided by the canonical
reprogramming factors. The importance of this study is not simply the boost to reprogramming efficiency delivered
by lincRNA-RoR, but it is also the suggestion that modulating the p53 network, in a variety of ways is a general
mechanism required for cellular reprogramming.
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Take Five for Efficient iPSC Production
Efforts to exploit the therapeutic potential of iPSCs have been hampered by low efficiency and potentially mutagenic
genomic alterations associated with viral-mediated cellular reprogramming. Warren et al. (2010) address both of these
issues by developing safe and efficient methods to redirect cell fate. Their method, which relies on the repeated admin-
istration of synthetic modified mRNAs encoded by five of the known pluripotency transcription factors (Klf4, c-Myc, Oct4,
Sox2, and Lin28), avoids the pitfalls of the established DNA-based methods by facilitating the transient and nonmuta-
genic introduction of pluripotency factors. Furthermore, this new method increases the efficiency and rapidity of cellular
reprogramming. The best cases of viral-mediated reprogramming occur with an efficiency of less than 0.1% over
a 4 week period. Now, with mRNA-mediated reprogramming, iPSCs can be generated with efficiencies of more than
4% in just over 2 weeks. The authors show that these same improvements also apply to the differentiation of iPSCs,
with transient transfection of the myogenic mRNA, MYOD, directing RNA-iPSCs to the myofiber fate. Transfection of
other factors, such as the lincRNA-RoR (Loewer et al., 2010, profiled above), to the reprogramming mRNA cocktail prom-
ises to further improve the efficiency of iPSC generation. This recent progress will not only improve the feasibility of iPSC
treatments but will also enable the dissection and analysis of the changes that drive cell reprogramming. By providing
a relatively simple method that allows consistent and temporal control of reprogramming factors, this paper should be
of great interest to clinicians and basic scientists.
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with Oct4 alone give rise tomature blood
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eosinophils and basophils. Photo of
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M. Bhatia.Fibroblast Conversion: There Will Be Blood
Direct conversion of one cell type into another is one approach that circumvents
the oncogenic potential sometimes associated with partially reprogrammed iPSC
intermediates. Szabo et al. (2010) now describe the direct conversion of human
fibroblasts into multilineage hematopoietic progenitors. These findings follow in
the wake of two studies earlier this year reporting the direct conversion of mouse
fibroblasts into neurons or cardiomyocytes. In the current work, Szabo et al.
monitor the progress of human dermal fibroblasts as they become multipotent
hematopoietic progenitors that give rise to erythrocytes, platelets, and all varieties
of white blood cells. Ectopic expression of Oct4, one of the factors typically em-
ployed for iPSC generation, initiates the hematopoietic program by usurping the
role of Oct4-related transcription factors known to be required for hematopoiesis.
When expressed in fibroblasts, Oct4 does not bind to the promoters of the stem
cell-inducing genes Nanog and c-Myc, as it does during iPSC generation, but
instead it appears to stimulate the expression of factors that activate the multipo-tent blood cell progenitor fate while preventing the acquisition of an embryonic-like fate. This study provides the first
evidence for direct conversion of human fibroblasts into multilineage precursors. Given that transduction of fibroblasts
with the lentivirus-encoded reprogramming factor carries the risk of host antiviral immune activation, it may be beneficial
to elicit this reprogramming event by other means as this approach moves closer to therapeutic use. One possibility may
be to adapt the mRNA-reprogramming method described by Warren et al. (2010, profiled above).
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